Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $19.6250.

A number of research analysts have recently commented on the company. Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They issued a “hold” rating and a $10.00 price target for the company. Jefferies Financial Group upgraded Bicycle Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC opened at $5.30 on Wednesday. Bicycle Therapeutics has a one year low of $5.03 and a one year high of $10.84. The company has a market cap of $367.66 million, a price-to-earnings ratio of -1.46 and a beta of 1.65. The firm has a 50 day simple moving average of $6.09 and a 200 day simple moving average of $6.88.

Insider Activity

In related news, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the transaction, the chief financial officer owned 87,081 shares in the company, valued at $565,155.69. This trade represents a 4.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the sale, the chief executive officer owned 618,996 shares in the company, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 38,029 shares of company stock worth $251,966. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCYC. Fcpm Iii Services B.V. raised its stake in shares of Bicycle Therapeutics by 0.5% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company’s stock valued at $24,556,000 after acquiring an additional 16,100 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock worth $22,911,000 after purchasing an additional 258,000 shares during the last quarter. Westfield Capital Management Co. LP grew its stake in shares of Bicycle Therapeutics by 2.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company’s stock worth $21,353,000 after purchasing an additional 63,483 shares during the last quarter. GSK plc acquired a new stake in Bicycle Therapeutics in the fourth quarter valued at $10,829,000. Finally, Long Focus Capital Management LLC raised its position in Bicycle Therapeutics by 7.7% during the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after purchasing an additional 101,402 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.